ochratoxin a has been researched along with Fatty Liver, Nonalcoholic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, HJ; Chen, TW; Ding, XF; Li, JJ; Ma, N; Ni, QZ; Qiu, XS; Wang, YK; Xia, J; Xie, D; Xu, S; Yu, DZ; Zhang, FK; Zheng, QW; Zhu, B | 1 |
| Cherrington, NJ; Frost, KL; Goedken, M; Jilek, JL; Marie, S; Myers, CM; Wright, SH | 1 |
2 other study(ies) available for ochratoxin a and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Ochratoxin A Induces Steatosis via PPARĪ³-CD36 Axis.
Topics: Animals; CD36 Antigens; Chemical and Drug Induced Liver Injury; Hep G2 Cells; Hepatocytes; Humans; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Ochratoxins; PPAR gamma | 2021 |
Attenuated Ochratoxin A Transporter Expression in a Mouse Model of Nonalcoholic Steatohepatitis Protects against Proximal Convoluted Tubule Toxicity.
Topics: Animals; Disease Models, Animal; Humans; Kidney; Mice; Mycotoxins; Non-alcoholic Fatty Liver Disease; Ochratoxins; Organic Anion Transporters; Protein Isoforms; Thioacetamide | 2022 |